title: Angiogenesis without functional outcome after mononuclear stem cell transplant in a doxorubicin-induced dilated myocardiopathy murine model.
abstract: OBJECTIVE
  Cell transplantation is considered a novel approach in the treatment of myocardiopathy. The objective of this study was to evaluate the effects of autologous mononuclear stem cell therapy in doxorubicin-induced dilated myocardiopathy by conducting both functional and histopathologic analysis.
  
  
  METHODS
  Seventy male rats were doxorubicin injected intraperitoneally for 2 weeks. At 1 month, the animals that had demonstrated left ventricular ejection fractions less than 40% were randomly divided into a mononuclear stem cell group and controls. Mononuclear stem cells were isolated. All animals underwent echocardiographic study: baseline, pre-cell therapy, and at 1 month post-cell therapy, and analyzed by the nonparametric Mann-Whitney test. Transplants were performed by subepicardial injections. Standard staining was performed.
  
  
  RESULTS
  Twenty-three animals were randomly treated: mononuclear stem cell and control groups, with 11 rats completing the study. Cell viability was 85%. Mononuclear stem cells (n=5; 5x106 cells /300 microL medium) and control (n=6; 300 microL medium) were used. The resulting left ventricular ejection fraction in the cell therapy group was not significantly different compared with controls (p=0.54). New vessels were demonstrated in the subepicardial region.
  
  
  CONCLUSIONS
  Autologous mononuclear stem cell therapy was not functionally effective in doxorubicin-induced dilated myocardiopathy in the animal model under study with the experimental conditions, despite occurrence of angiogenic activity.
authors.affiliation: Pos-Graduacao de Ciencias da Saude da Universidade Pontificia Universidade Catolica do Parana', Curitiba, Parana' - Brazil. katherinecarv@gmail.com
authors.forename: K A T
authors.initials: KA
authors.lastname: Carvalho
authors.forename: R B
authors.initials: RB
authors.lastname: Simeoni
authors.forename: L C
authors.initials: LC
authors.lastname: Guarita-Souza
authors.forename: J C
authors.initials: JC
authors.lastname: Francisco
authors.forename: E
authors.initials: E
authors.lastname: Abdelwahid
authors.forename: N I
authors.initials: NI
authors.lastname: Myiague
authors.forename: J C
authors.initials: JC
authors.lastname: Chachques
authors.forename: L A
authors.initials: LA
authors.lastname: Rivetti
authors.forename: L
authors.initials: L
authors.lastname: Oliveira
authors.forename: M
authors.initials: M
authors.lastname: Malvezzi
authors.forename: M
authors.initials: M
authors.lastname: Olandoski
authors.forename: W
authors.initials: W
authors.lastname: Gremski
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation; D009202:Cardiomyopathies / Q000139:chemically induced / Q000628:therapy*; D004195:Disease Models, Animal; D008297:Male; D018919:Neovascularization, Physiologic; D051381:Rats; D017208:Rats, Wistar; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous